JP2006506466A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006506466A5 JP2006506466A5 JP2005505545A JP2005505545A JP2006506466A5 JP 2006506466 A5 JP2006506466 A5 JP 2006506466A5 JP 2005505545 A JP2005505545 A JP 2005505545A JP 2005505545 A JP2005505545 A JP 2005505545A JP 2006506466 A5 JP2006506466 A5 JP 2006506466A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- medicament
- effective amount
- patient
- need
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims 71
- 150000001875 compounds Chemical class 0.000 claims 66
- 239000008194 pharmaceutical composition Substances 0.000 claims 38
- 206010028980 Neoplasm Diseases 0.000 claims 21
- 125000003710 aryl alkyl group Chemical group 0.000 claims 21
- 201000011510 cancer Diseases 0.000 claims 21
- 239000002671 adjuvant Substances 0.000 claims 20
- 125000003118 aryl group Chemical group 0.000 claims 20
- 239000003085 diluting agent Substances 0.000 claims 20
- 239000000546 pharmaceutical excipient Substances 0.000 claims 20
- 125000000547 substituted alkyl group Chemical group 0.000 claims 17
- 238000004519 manufacturing process Methods 0.000 claims 15
- 125000000217 alkyl group Chemical group 0.000 claims 13
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 12
- 230000004770 neurodegeneration Effects 0.000 claims 12
- 208000015122 neurodegenerative disease Diseases 0.000 claims 12
- 238000002560 therapeutic procedure Methods 0.000 claims 12
- 239000011701 zinc Substances 0.000 claims 12
- 229910052725 zinc Inorganic materials 0.000 claims 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims 11
- 125000001072 heteroaryl group Chemical group 0.000 claims 11
- 229910052739 hydrogen Inorganic materials 0.000 claims 11
- 239000001257 hydrogen Substances 0.000 claims 11
- 208000008589 Obesity Diseases 0.000 claims 10
- 239000000883 anti-obesity agent Substances 0.000 claims 10
- 229940125710 antiobesity agent Drugs 0.000 claims 10
- 125000004404 heteroalkyl group Chemical group 0.000 claims 10
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 10
- 235000020824 obesity Nutrition 0.000 claims 10
- 150000002431 hydrogen Chemical class 0.000 claims 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 9
- 239000012453 solvate Substances 0.000 claims 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 8
- 125000003342 alkenyl group Chemical group 0.000 claims 7
- 239000002246 antineoplastic agent Substances 0.000 claims 7
- 208000024827 Alzheimer disease Diseases 0.000 claims 6
- 201000003076 Angiosarcoma Diseases 0.000 claims 6
- 208000003174 Brain Neoplasms Diseases 0.000 claims 6
- 206010006187 Breast cancer Diseases 0.000 claims 6
- 208000026310 Breast neoplasm Diseases 0.000 claims 6
- 208000005243 Chondrosarcoma Diseases 0.000 claims 6
- 206010009944 Colon cancer Diseases 0.000 claims 6
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims 6
- 208000001258 Hemangiosarcoma Diseases 0.000 claims 6
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 6
- 208000024777 Prion disease Diseases 0.000 claims 6
- 206010060862 Prostate cancer Diseases 0.000 claims 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 6
- 206010038389 Renal cancer Diseases 0.000 claims 6
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims 6
- 206010064930 age-related macular degeneration Diseases 0.000 claims 6
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 6
- 230000033115 angiogenesis Effects 0.000 claims 6
- 208000029742 colonic neoplasm Diseases 0.000 claims 6
- 229910052802 copper Inorganic materials 0.000 claims 6
- 239000010949 copper Substances 0.000 claims 6
- 201000010982 kidney cancer Diseases 0.000 claims 6
- 229940127084 other anti-cancer agent Drugs 0.000 claims 6
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 6
- 125000003107 substituted aryl group Chemical group 0.000 claims 6
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 6
- 230000002159 abnormal effect Effects 0.000 claims 5
- 125000004474 heteroalkylene group Chemical group 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 1
- RAXXELZNTBOGNW-UHFFFAOYSA-O Imidazolium Chemical compound C1=C[NH+]=CN1 RAXXELZNTBOGNW-UHFFFAOYSA-O 0.000 claims 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-O Pyrrolidinium ion Chemical compound C1CC[NH2+]C1 RWRDLPDLKQPQOW-UHFFFAOYSA-O 0.000 claims 1
- 230000001594 aberrant effect Effects 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical class C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 claims 1
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 1
- 0 CC[N+](CC)(CC)CCCCC*CC*CC[N+](CC)(CC)CC Chemical compound CC[N+](CC)(CC)CCCCC*CC*CC[N+](CC)(CC)CC 0.000 description 11
- ZNEOHLHCKGUAEB-UHFFFAOYSA-N C[N+](C)(C)c1ccccc1 Chemical compound C[N+](C)(C)c1ccccc1 ZNEOHLHCKGUAEB-UHFFFAOYSA-N 0.000 description 2
- JBKPUQTUERUYQE-UHFFFAOYSA-O C[n+]1c(/C=N\O)cccc1 Chemical compound C[n+]1c(/C=N\O)cccc1 JBKPUQTUERUYQE-UHFFFAOYSA-O 0.000 description 2
- JWLVVWBHILZADA-UHFFFAOYSA-N CC(CC[N+](C)(C)C)O Chemical compound CC(CC[N+](C)(C)C)O JWLVVWBHILZADA-UHFFFAOYSA-N 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N CC(OCC[N+](C)(C)C)=O Chemical compound CC(OCC[N+](C)(C)C)=O OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- YUVRFZXUICLHML-UHFFFAOYSA-N CCC(CC)(CC[N+](C)(C)C)C[N](C)(C)C Chemical compound CCC(CC)(CC[N+](C)(C)C)C[N](C)(C)C YUVRFZXUICLHML-UHFFFAOYSA-N 0.000 description 1
- IBZJNLWLRUHZIX-UHFFFAOYSA-N CCN1C=CN(C)C1 Chemical compound CCN1C=CN(C)C1 IBZJNLWLRUHZIX-UHFFFAOYSA-N 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-O CC[NH+](CC)CCOC(c(cc1)ccc1N)=O Chemical compound CC[NH+](CC)CCOC(c(cc1)ccc1N)=O MFDFERRIHVXMIY-UHFFFAOYSA-O 0.000 description 1
- WYFGXQCOMIYMIE-UHFFFAOYSA-N C[N+](C)(C)C1CC1 Chemical compound C[N+](C)(C)C1CC1 WYFGXQCOMIYMIE-UHFFFAOYSA-N 0.000 description 1
- AACHVWXCVWWMSI-UHFFFAOYSA-N C[N+](C)(C)CCCO Chemical compound C[N+](C)(C)CCCO AACHVWXCVWWMSI-UHFFFAOYSA-N 0.000 description 1
- JMIXRFUTQFPCLN-UHFFFAOYSA-N C[N+](C)(C)CCCOCCOC Chemical compound C[N+](C)(C)CCCOCCOC JMIXRFUTQFPCLN-UHFFFAOYSA-N 0.000 description 1
- NJICVKXEONIFAZ-UHFFFAOYSA-N C[N+](C)(C)CCOCCOC Chemical compound C[N+](C)(C)CCOCCOC NJICVKXEONIFAZ-UHFFFAOYSA-N 0.000 description 1
- BBTHTWPHAAPRGI-UHFFFAOYSA-N C[N+](C)(CCC1OCC1)Cc1ccccc1 Chemical compound C[N+](C)(CCC1OCC1)Cc1ccccc1 BBTHTWPHAAPRGI-UHFFFAOYSA-N 0.000 description 1
- ZHYRZMGVDRAROM-UHFFFAOYSA-O C[NH+](C)CCC1[O](CC[O](CC[N+](C)(C)C)=C)C1 Chemical compound C[NH+](C)CCC1[O](CC[O](CC[N+](C)(C)C)=C)C1 ZHYRZMGVDRAROM-UHFFFAOYSA-O 0.000 description 1
- PAFZNILMFXTMIY-UHFFFAOYSA-O [NH3+]C1CCCCC1 Chemical compound [NH3+]C1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-O 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/202,346 US20040019043A1 (en) | 2002-07-23 | 2002-07-23 | Thiomolybdate analogues and uses thereof |
| US43474202P | 2002-12-18 | 2002-12-18 | |
| US43695803A | 2003-05-12 | 2003-05-12 | |
| US10/447,585 US7189865B2 (en) | 2002-07-23 | 2003-05-28 | Thiomolybdate analogues and uses thereof |
| PCT/US2003/023031 WO2004009034A2 (en) | 2002-07-23 | 2003-07-22 | Thiomolybdate analogues and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006506466A JP2006506466A (ja) | 2006-02-23 |
| JP2006506466A5 true JP2006506466A5 (https=) | 2006-09-14 |
Family
ID=30773643
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005505545A Pending JP2006506466A (ja) | 2002-07-23 | 2003-07-22 | チオモリブデン酸類似物及びそれらの使用 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US7189865B2 (https=) |
| EP (1) | EP1556029B1 (https=) |
| JP (1) | JP2006506466A (https=) |
| KR (1) | KR20050053596A (https=) |
| CN (1) | CN100531732C (https=) |
| AU (1) | AU2003256704A1 (https=) |
| BR (1) | BR0312851A (https=) |
| CA (1) | CA2493127A1 (https=) |
| DK (1) | DK1556029T3 (https=) |
| EA (1) | EA200500250A1 (https=) |
| ES (1) | ES2448800T3 (https=) |
| HR (1) | HRP20050174A2 (https=) |
| IL (1) | IL166448A0 (https=) |
| MX (1) | MXPA05000870A (https=) |
| NO (1) | NO20050917L (https=) |
| PL (1) | PL374821A1 (https=) |
| PT (1) | PT1556029E (https=) |
| SI (1) | SI1556029T1 (https=) |
| WO (1) | WO2004009034A2 (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1115389B1 (en) * | 1998-09-25 | 2014-03-12 | PhilERA New Zealand Limited | Fructosamine oxidase: antagonists and inhibitors |
| AU4678300A (en) * | 1999-04-30 | 2000-11-17 | Slil Biomedical Corporation | Novel polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases |
| JP4743673B2 (ja) * | 1999-04-30 | 2011-08-10 | プロゲン ファーマシューティカルズ， インコーポレイテッド | ポリアミンおよび治療におけるそれらの使用 |
| AU2001297817A1 (en) * | 2000-11-08 | 2002-11-25 | Eli Lilly And Company | Antiviral therapies using polyamine or polyamine analog-amino acid conjugates |
| WO2003018595A2 (en) * | 2001-08-24 | 2003-03-06 | Maine Medical Center Research Institute | Copper-dependent non-traditional pro-inflammatory cytokine export and methods, compositions and kits relating thereto |
| IL161428A0 (en) * | 2001-10-16 | 2004-09-27 | Slil Biomedical Corp | Oligoamine derivatives, methods for the production thereof and pharmaceutical compositions containing the same |
| ATE555782T1 (de) | 2002-03-08 | 2012-05-15 | Philera New Zealand Ltd | Prävention und/oder behandlung von kardiovaskulären erkrankungen und/oder damit zusammenhängender herzinsuffizienz |
| CA2490541A1 (en) * | 2002-05-24 | 2003-12-04 | The Regents Of The University Of Michigan | Copper lowering treatment of inflammatory and fibrotic diseases |
| WO2004009072A2 (en) * | 2002-07-23 | 2004-01-29 | The Regents Of The University Of Michigan | Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies |
| US20060100278A1 (en) | 2002-08-20 | 2006-05-11 | Cooper Garth J S | Dosage forms and related therapies |
| MXPA05012722A (es) * | 2003-05-27 | 2006-05-25 | Attenuon Llc | Analogos de tiotungstato y sus usos. |
| WO2005082382A1 (en) * | 2004-02-23 | 2005-09-09 | Attenuon Llc | Formulations of thiomolybdate or thiotungstate compounds and uses thereof |
| AU2005217623A1 (en) * | 2004-02-24 | 2005-09-09 | Attenuon Llp | Inhibition of superoxide dismutase by tetrathiomolybdate: identification of new anti-angiogenic and antitumor agents |
| ES2449066T3 (es) | 2004-07-19 | 2014-03-18 | Philera New Zealand Limited | Síntesis de trietilentetraminas |
| JP5099620B2 (ja) * | 2006-10-26 | 2012-12-19 | 学校法人日本大学 | 筋萎縮性側索硬化症治療薬 |
| WO2008103421A1 (en) * | 2007-02-21 | 2008-08-28 | Ssv Therapeutics, Inc. | Adamantanamines and neramexane salts of thiomolybdic and thiotungstic acids |
| PL381862A1 (pl) | 2007-02-28 | 2008-09-01 | Trigendo Spółka Z Ograniczoną Odpowiedzialnością | Zastosowanie związków pirydyniowych i sposób leczenia |
| US20090028800A1 (en) * | 2007-07-27 | 2009-01-29 | Peeples William H | Method of Treating Postpartum Depression and Aggression |
| US20110028513A1 (en) * | 2008-03-31 | 2011-02-03 | Lang Zhuo | Method for treating neurological disorders with imidazolium and imidazolinium compounds |
| JP6285164B2 (ja) * | 2013-12-05 | 2018-02-28 | デクセリアルズ株式会社 | 化合物、熱硬化性樹脂組成物、及び熱硬化性シート |
| ES2956768T3 (es) * | 2016-02-23 | 2023-12-27 | Vanderbilt Chemicals Llc | Sales de molibdato binucleares que contienen azufre de amonio cuaternario como aditivos de lubricantes |
| US11510944B2 (en) | 2017-12-04 | 2022-11-29 | Alexion Pharmaceuticals, Inc. | Bis-choline tetrathiomolybdate for treating Wilson disease |
| US11419832B2 (en) | 2017-12-04 | 2022-08-23 | Alexion Pharmaceuticals, Inc. | Bis-choline tetrathiomolybdate for treating Wilson Disease |
| EP3749417A1 (en) * | 2018-02-06 | 2020-12-16 | Alexion Pharma International Operations Unlimited Company | Crystalline particles of bis-choline tetrathiomolybdate |
| JP7394773B2 (ja) * | 2018-02-15 | 2023-12-08 | アレクシオン・ファーマ・インターナショナル・オペレーションズ・リミテッド | ビス－コリンテトラチオモリブデートの製造方法 |
| WO2020148654A2 (en) | 2019-01-14 | 2020-07-23 | Alexion Pharma International Operations Unlimited Company | Methods for preparing ammonium tetrathiomolybdate |
| US11471497B1 (en) | 2019-03-13 | 2022-10-18 | David Gordon Bermudes | Copper chelation therapeutics |
| US12458599B2 (en) | 2020-10-07 | 2025-11-04 | Cti Vascular Ag | Bioactivatable devices and related methods |
| US20240100088A1 (en) * | 2021-01-31 | 2024-03-28 | Alexion Pharmaceuticals, Inc. | Novel formulation for treating copper metabolism-associated diseases or disorders |
| WO2023086873A1 (en) * | 2021-11-10 | 2023-05-19 | Reverspah Llc | Methods and compositions for treating cancer |
| CN114042083B (zh) * | 2021-12-06 | 2022-08-30 | 湖南师范大学 | 四硫代钼酸盐的增肌及治疗应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2909541A (en) | 1955-01-07 | 1959-10-20 | Inst Francais Du Petrole | Nitrogenous thiomolybdates |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4400282A (en) | 1980-12-05 | 1983-08-23 | Gulf Research & Development Company | Lubricating oils containing quaternary ammonium thiomolybdates |
| US4343746A (en) | 1980-12-10 | 1982-08-10 | Gulf Research & Development Company | Quaternary ammonium thiomolybdates |
| US4430443A (en) * | 1982-07-20 | 1984-02-07 | Exxon Research And Engineering Co. | Supported carbon-containing molybdenum and tungsten sulfide catalysts, their preparation and use |
| GB8504253D0 (en) | 1985-02-19 | 1985-03-20 | Ici Plc | Electrostatic spraying apparatus |
| DE3815221C2 (de) | 1988-05-04 | 1995-06-29 | Gradinger F Hermes Pharma | Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen |
| US5698155A (en) | 1991-05-31 | 1997-12-16 | Gs Technologies, Inc. | Method for the manufacture of pharmaceutical cellulose capsules |
| US5639725A (en) | 1994-04-26 | 1997-06-17 | Children's Hospital Medical Center Corp. | Angiostatin protein |
| US5970974A (en) | 1995-03-14 | 1999-10-26 | Siemens Aktiengesellschaft | Dosating unit for an ultrasonic atomizer device |
| DE69605025T2 (de) | 1995-03-14 | 2000-07-20 | Siemens Ag | Ultraschallzerstäuber mit abnehmbarer präzisionsdosiereinheit |
| US5954047A (en) | 1997-10-17 | 1999-09-21 | Systemic Pulmonary Development, Ltd. | Methods and apparatus for delivering aerosolized medication |
| US6953557B1 (en) | 1997-10-17 | 2005-10-11 | Ebara Corporation | Process and apparatus for treating semiconductor production exhaust gases |
| IL141550A0 (en) * | 1998-09-04 | 2002-03-10 | Univ Michigan | Methods and compositions for the prevention or treatment of cancer |
| CN1262226A (zh) | 1999-12-03 | 2000-08-09 | 中国科学院兰州化学物理研究所 | 硫代钼酸盐及其制备方法和用途 |
| CA2490541A1 (en) * | 2002-05-24 | 2003-12-04 | The Regents Of The University Of Michigan | Copper lowering treatment of inflammatory and fibrotic diseases |
| WO2004009072A2 (en) * | 2002-07-23 | 2004-01-29 | The Regents Of The University Of Michigan | Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies |
-
2003
- 2003-05-28 US US10/447,585 patent/US7189865B2/en not_active Expired - Lifetime
- 2003-07-22 JP JP2005505545A patent/JP2006506466A/ja active Pending
- 2003-07-22 BR BR0312851-2A patent/BR0312851A/pt not_active IP Right Cessation
- 2003-07-22 WO PCT/US2003/023031 patent/WO2004009034A2/en not_active Ceased
- 2003-07-22 KR KR1020057001310A patent/KR20050053596A/ko not_active Ceased
- 2003-07-22 CA CA002493127A patent/CA2493127A1/en not_active Abandoned
- 2003-07-22 CN CNB038225557A patent/CN100531732C/zh not_active Expired - Lifetime
- 2003-07-22 ES ES03765973.7T patent/ES2448800T3/es not_active Expired - Lifetime
- 2003-07-22 SI SI200332340T patent/SI1556029T1/sl unknown
- 2003-07-22 EA EA200500250A patent/EA200500250A1/ru unknown
- 2003-07-22 HR HR20050174A patent/HRP20050174A2/hr not_active Application Discontinuation
- 2003-07-22 DK DK03765973.7T patent/DK1556029T3/en active
- 2003-07-22 PT PT37659737T patent/PT1556029E/pt unknown
- 2003-07-22 MX MXPA05000870A patent/MXPA05000870A/es active IP Right Grant
- 2003-07-22 PL PL03374821A patent/PL374821A1/xx not_active Application Discontinuation
- 2003-07-22 EP EP03765973.7A patent/EP1556029B1/en not_active Expired - Lifetime
- 2003-07-22 AU AU2003256704A patent/AU2003256704A1/en not_active Abandoned
-
2005
- 2005-01-23 IL IL16644805A patent/IL166448A0/xx unknown
- 2005-02-21 NO NO20050917A patent/NO20050917L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006506466A5 (https=) | ||
| KR102303052B1 (ko) | Jak 저해제를 포함하는 제약 조성물 | |
| TWI699359B (zh) | ４ｈ-吡咯［３,２-ｃ］吡啶-４-酮衍生物 | |
| JP2005535698A5 (https=) | ||
| JP7234250B2 (ja) | 置換大環状インドール誘導体 | |
| US20210292341A1 (en) | Macrocyclic indole derivatives | |
| JP2019526546A5 (https=) | ||
| UA121482C2 (uk) | Комбінація інгібітору протеасом, яким є бортезоміб, та інгібітору c-met для лікування множинної мієломи | |
| JP2005508337A5 (https=) | ||
| JP2019533660A5 (https=) | ||
| JP2006518731A5 (https=) | ||
| JP2007516234A5 (ja) | チオタングステートアナログ及びその使用 | |
| JP2007521313A5 (https=) | ||
| RU2713179C2 (ru) | Антимитотические амиды для лечения рака и пролиферативных заболеваний | |
| RU2468015C2 (ru) | Полиморфные формы деферасирокса (icl670a) | |
| CN101361741A (zh) | 异噁唑啉类衍生物抗肿瘤新用途 | |
| JP2004517151A5 (https=) | ||
| CN106459011B (zh) | 作为抗肿瘤化合物的σ-2受体配体药物缀合物、其合成方法及其用途 | |
| RU2006117627A (ru) | Новые применения в медицине соединений, обладающих антагонистической активностью по отношению к св1, и комбинированное лечение с применением этих соединений | |
| US11986442B2 (en) | Inhibition of respiratory complex III by ligands that interact with a regulatory switch | |
| CN101235013A (zh) | 结晶型1-（3-氟苯基）-5-甲基-2-（1h）吡啶酮、其制备方法、及其组合物和应用 | |
| KR20100038061A (ko) | 리마프로스트를 함유하는, 암화학 요법에 기인하는 말초신경장애 예방, 치료 및/또는 증상 경감제 | |
| RU2018141584A (ru) | Триазолы для регуляции гомеостаза внутриклеточного кальция | |
| JP2005511571A5 (https=) | ||
| JP2019517474A5 (https=) |